Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.47 |
| ▸ | BRD2 | P25440 | 4/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658898 | 0.75 | BRD4 (0.49) | BRD4BRD2ERN1CREBBP | |
| SCHEMBL9932071 | 0.74 | BRD4 (0.57) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL583542 | 0.73 | BRD4 (0.51) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL22533011 | 0.71 | BRD4 (0.53) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL31392869 | 0.71 | BRD4 (0.53) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL16861736 | 0.71 | BRD4 (0.50) | BRD4BRD2CREBBPBRD3 | |
| SCHEMBL14678367 | 0.69 | BRD4 (0.66) | BRD4BRD2CREBBPBRD3 | |
| SCHEMBL19726799 | 0.69 | BRD4 (0.48) | BRD4BRD2ERN1CREBBP | |
| SCHEMBL15836986 | 0.68 | BRD4 (0.54) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL1502641 | 0.68 | BRD4 (0.49) | BRD4BRD2ERN1CREBBPBRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-4139296-B1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| CN-116323588-A | Compounds and methods for CD73 modulation and indications therefor | 奥普纳生物有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4139296-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Immuno Oncology, SA (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | disclosed |
| WO-2021216898-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | BRD4 3382/4885BRD2 4315/4885ERN1 3496/4885 |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | BRD4 3382/4885BRD2 4315/4885ERN1 3496/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | BRD4 3382/4885BRD2 4315/4885ERN1 3496/4885 |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | BRD4 3362/4885BRD2 4316/4885ERN1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.